Biotechnology and genetic engineering is where new ideas collide with sophisticated innovation and discovery, often resulting in expanded economic and human health potential. As a result, IP strategy often reflects the core of a fortified monetization strategy. Lawyers seeking to advance client objectives must understand the chemistry and technology this discipline requires. Rothwell Figg delivers both the technical and legal know-how to help private and public sector clients own and leverage their exciting technological and scientific advances on a global scale.
Our firm represents the individuals and institutions involved in extraordinary advances in life science technology such as biotech companies, universities, hospitals, and technology centers involved in research and development for this industry. Such clients value our deep bench of experience not only in the law, but also in chemistry, molecular biology, engineering, and genetics, allowing us to better advise on advancing their ownership and commercialization of such complex IP assets.
We provide legal counsel on all areas of patent application drafting and prosecution, opinions, inter partes review, post-grant review, and interferences before the U.S. Patent and Trademark Office (USPTO), as well as in litigation in district courts across the country. Our team is committed to remaining well-informed regarding client competitors and use this intelligence to draft the broadest possible claims to maximize market position. Because we offer veteran representation in both prosecution and litigation, we anticipate and mitigate obstacles to progress in real time and before such problems can become serious roadblocks and disruptive to bigger picture objectives.
Our lawyers are fluent in communicating effectively with inventors, business professionals, and in-house counsel alike. As a result, inventors have a high level of comfort talking in detail about complex subject matter such as the CRISPR/Cas system and other engineered nucleases used for genetic modification. Our experience in antibody technology and biosimilars puts us on the cutting edge of complex, life-saving discovery. We understand and have conducted experiments similar to those of the scientists we represent, giving us the background and experience to guide inventors as to additional lines of investigation that may further support and expand their intellectual property.
Our firm delivers the requisite erudition, honed technical acuity, and hands-on skill in and understanding of biotech, pharmaceutical, and medical devices needed to advance and monetize intangible assets across the biotechnology and genetic engineering industry. Our experience includes advising on IP-related issues involving:
- Combinatorial chemistry
- Gene therapy
- Genetically modified organisms (GMOs)
- Medical imaging and display
- Molecular biology
- Pharmaceuticals and drug discovery
- Plant genetics
- Transgenic technology
- Speaking Engagement, Boston, MA,
- Speaking Engagement, Paris, France,
- Speaking Engagement,
- Speaking Engagement, November 19-20, 2020
- Speaking Engagement,
- Speaking Engagement, Cambridge, MA,
- Speaking Engagement, Philadelphia, PA, March 28-29, 2019
- Speaking Engagement, San Antonio, TX, March 30-April 1, 2016